3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
27
Lymphoma, Non-Hodgkin
21
Leukemia, Myeloid, Acute
15
Lymphoma
9
Hodgkin Disease
9
Neoplasms, Plasma Cell
5
Myelodysplastic Syndromes
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Leukemia
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Recurrence
2
Pancreatic Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Warts
1
Pinealoma
1
Paraproteinemias
1
Ovarian Neoplasms
1
Neutropenia
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Infections
1
Immunologic Deficiency Syndromes
1
Hematologic Neoplasms
1
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
plerixafor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled